SUNNYVALE, Calif., July 26,
2024 /CNW/ - Willow Biosciences Inc. ("Willow"
or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased
to announce the voting results from its annual general and special
meeting of shareholders held on July 26,
2024 (the "Meeting"). A total of 27,685,611 common
shares, representing approximately 21.74% of the Company's issued
and outstanding shares were represented at the meeting.
The shareholders approved the setting of the number of directors
of Willow at 5 directors, and the following nominees were elected
as directors of Willow for the ensuing year with the specific
voting results being as follows:
|
Votes For
|
Votes
Withheld
|
|
Director
|
#
|
%
|
#
|
%
|
|
Donald
Archibald
|
19,248,325
|
77.19 %
|
5,686,936
|
22.81 %
|
|
Al Foreman
|
24,905,181
|
99.88 %
|
30,080
|
0.12 %
|
|
Raffi
Asadorian
|
21,273,181
|
85.31 %
|
3,662,080
|
14.69 %
|
|
Dr. Jim
Lalonde
|
24,905,317
|
99.88 %
|
29,944
|
0.12 %
|
|
Dr. Chris
Savile
|
24,905,182
|
99.88 %
|
30,079
|
0.12 %
|
In addition, shareholders approved the appointment of KPMG LLP
as the Company's auditor for the ensuing year (86.77% of the votes
cast being in favour). The shareholders also approved the grant of
unallocated share awards issuable under Willow's share award
incentive plan pursuant to the requirements of the Toronto Stock
Exchange. For complete voting results on all matters approved at
the Meeting, please see the Company's Report of Voting Results
dated July 26, 2024 available on
SEDAR+ at www.sedarplus.ca.
About Willow Biosciences Inc.
Willow develops biobased processes to manufacture ingredients
for the pharmaceutical, food and beverage and consumer markets.
Willow's FutureGrownTM and BioOxiTM platforms
enable large-scale production with sustainability at its core.
Willow's R&D team has a proven track record of developing and
commercializing bio-based manufacturing processes and products to
benefit our B2B partners and their customers.
FutureGrown™ and BioOxi™ are registered trademarks of Willow
Biosciences Inc.
For more information, visit www.willowbio.com
SOURCE Willow Biosciences Inc.
